Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
NCT05989126
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetic Macular Edema (DME)
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
DRUG:
aflibercept 8 mg PFS
Sponsor
Regeneron Pharmaceuticals